171 related articles for article (PubMed ID: 37634215)
41. Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1.
Hong SH; Hwang HJ; Son DH; Kim ES; Park SY; Yoon YE
FEBS Open Bio; 2023 Apr; 13(4):724-735. PubMed ID: 36808829
[TBL] [Abstract][Full Text] [Related]
42. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
43. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.
Wee ZN; Li Z; Lee PL; Lee ST; Lim YP; Yu Q
Cell Rep; 2014 Jul; 8(1):204-16. PubMed ID: 24953652
[TBL] [Abstract][Full Text] [Related]
44. Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.
Raychaudhuri R; Ujjani C
Onco Targets Ther; 2022; 15():193-199. PubMed ID: 35250278
[TBL] [Abstract][Full Text] [Related]
45. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
46. Nicotine associated breast cancer in smokers is mediated through high level of EZH2 expression which can be reversed by methyltransferase inhibitor DZNepA.
Kumari K; Das B; Adhya A; Chaudhary S; Senapati S; Mishra SK
Cell Death Dis; 2018 Feb; 9(2):152. PubMed ID: 29396474
[TBL] [Abstract][Full Text] [Related]
47. The role of tazemetostat in relapsed/refractory follicular lymphoma.
von Keudell G; Salles G
Ther Adv Hematol; 2021; 12():20406207211015882. PubMed ID: 34104370
[TBL] [Abstract][Full Text] [Related]
48. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
[TBL] [Abstract][Full Text] [Related]
49. Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus.
Nehme Z; Pasquereau S; Haidar Ahmad S; El Baba R; Herbein G
EBioMedicine; 2022 Jun; 80():104056. PubMed ID: 35596973
[TBL] [Abstract][Full Text] [Related]
50. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
51. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
[TBL] [Abstract][Full Text] [Related]
52. MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma.
Zhang X; Zhang X; Wang T; Wang L; Tan Z; Wei W; Yan B; Zhao J; Wu K; Yang A; Zhang R; Jia L
Cancer Lett; 2018 Jul; 426():98-108. PubMed ID: 29653269
[TBL] [Abstract][Full Text] [Related]
53. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.
Kuser-Abali G; Alptekin A; Cinar B
Epigenetics; 2014 Apr; 9(4):634-43. PubMed ID: 24499724
[TBL] [Abstract][Full Text] [Related]
55. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2.
Wu Y; Hu L; Liang Y; Li J; Wang K; Chen X; Meng H; Guan X; Yang K; Bai Y
Mol Cancer; 2017 Aug; 16(1):150. PubMed ID: 28854977
[TBL] [Abstract][Full Text] [Related]
56. Morphoproteomics and Biomedical Analytics Identify the c-Myc, EZH2, Sirt1 and CXCR4 Pathways as Potential Blocks to Differentiation Leading to Proliferation and Metastatic Potential in Sinonasal Undifferentiated Carcinoma (SNUC) and Provide Therapeutic Options: A Case Study.
Brown RE; Roy S; McGuire MF
Ann Clin Lab Sci; 2018 Sep; 48(5):659-664. PubMed ID: 30373873
[TBL] [Abstract][Full Text] [Related]
57. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
Perotti V; Baldassari P; Molla A; Nicolini G; Bersani I; Grazia G; Benigni F; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2019 May; 38(22):4384-4396. PubMed ID: 30710146
[TBL] [Abstract][Full Text] [Related]
58. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
[TBL] [Abstract][Full Text] [Related]
59. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
60. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma.
Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L
Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
